Search

Your search keyword '"Jie, Xina"' showing total 13 results
Start Over Author "Jie, Xina"
13 results on '"Jie, Xina"'

6. Additional file 1 of Bupi Yishen formula attenuates kidney injury in 5/6 nephrectomized rats via the tryptophan-kynurenic acid-aryl hydrocarbon receptor pathway

Author

Mo, Yenan, Jie, Xina, Wang, Lixin, Ji, Chunlan, Gu, Yueyu, Lu, Zhaoyu, and Liu, Xusheng

Abstract

Additional file 1: Suppl. Table 1. Information of components in Bupi Yishen Formula (BYF). Suppl. Item1. Method of high-performance liquid chromatography in chemical analysis of BYF Extract. Suppl. Item2. Reagents used for Liquid chromatography–tandem mass spectrometry. Suppl. Fig. 1. HPLC analysis of Bupi Yishen Formula in present study(A) and previous study(B). The denotation peaks 1–7: (1) Calycosin-7-O-Glc, (2) (E)-THSG, (3) Astragulin, (4) Rosmarinic acid, (5) Salvianolic acid A, (6) Salvianolic acid B, (7) Calycosin.

Published
2021
Full Text
View/download PDF

8. Effectiveness of Chinese herbal medicine combined with Western medicine on deferring dialysis initiation for nondialysis chronic kidney disease stage 5 patients: a multicenter prospective nonrandomized controlled study

Author

Wu, Yifan, primary, Li, Chuang, additional, Zhang, Lei, additional, Zou, Chuan, additional, Xu, Peng, additional, Wen, Zehuai, additional, Ouyang, Wenwei, additional, Yang, Nizhi, additional, Zhang, Min, additional, Lin, Qizhan, additional, Lu, Fuhua, additional, Wang, Lixin, additional, Bao, Kun, additional, Zhao, Daixin, additional, Fu, Lizhe, additional, Guo, Xinfeng, additional, Yang, Lihong, additional, Ou, Aihua, additional, He, Zehui, additional, Weng, Heng, additional, Li, Jianmin, additional, Shi, Wei, additional, Wang, Xiaoqin, additional, Song, Liqun, additional, Zhan, Yongli, additional, Sun, Wei, additional, Wei, Lianbo, additional, Wang, Niansong, additional, Gui, Dingkun, additional, Zhan, Jihong, additional, Lu, Ying, additional, Chen, Hongyu, additional, Liu, Yuning, additional, Yang, Hongtao, additional, Chen, Ming, additional, Wang, Yiping, additional, Zhang, Peiqing, additional, Deng, Yueyi, additional, Meng, Lanfen, additional, Cheng, Xiaohong, additional, Li, Feng, additional, Yu, Dajun, additional, Xu, Damin, additional, Fang, Jing’ai, additional, Li, Hongyan, additional, Fu, Junzhou, additional, Xie, Yuansheng, additional, Li, Wenge, additional, Zhao, Jinghong, additional, Huang, Yuanhang, additional, Lu, Zhaoyu, additional, Su, Guobin, additional, Zhang, La, additional, Qin, Xindong, additional, Xu, Yuan, additional, Peng, Yu, additional, Hou, Haijing, additional, Deng, Lili, additional, Liu, Hui, additional, Jie, Xina, additional, Liu, Lichang, additional, Tang, Fang, additional, Pei, Hongfei, additional, Li, Ping, additional, Mao, Wei, additional, and Liu, Xusheng, additional

Published
2021
Full Text
View/download PDF

10. Telehealth for the management of blood pressure in patients with chronic kidney disease: A systematic review.

Author

Luo, Li, Ye, Meiqin, Tan, Jiaowang, Huang, Qiong, Qin, Xindong, Peng, Suyuan, Wang, Yikun, Zou, Tao, Jie, Xina, Liu, Xusheng, and Wu, Yifan

Subjects
TELEMEDICINE, BLOOD pressure measurement, KIDNEY diseases, SYSTEMATIC reviews, RANDOMIZED controlled trials, HYPERTENSION epidemiology, BLOOD pressure, CHRONIC kidney failure, CLINICAL trials, CREATININE, GLOMERULAR filtration rate, HEMODIALYSIS, HYPERTENSION, MEDICAL information storage & retrieval systems, MEDLINE
Abstract

Background: Most patients with chronic kidney disease (CKD) fail to achieve blood pressure (BP) management as recommended. Meanwhile, the effects of promising intervention and telehealth on BP control in CKD patients remain unclear. We aimed to evaluate the efficacy of telehealth for BP in CKD non-dialysis patients.Methods: Databases including MEDLINE, EMBASE, CENTRAL, CNKI, Wanfang, VIP and CBM were systematically searched for randomised controlled trials or quasi-randomised controlled trials on telehealth for BP control of CKD3-5 non-dialysis patients. We analysed systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), serum creatinine, and estimated glomerular filtration rate (eGFR) with a fixed-effects model.Results: Three studies, with total 680 subjects, were included in our systematic review and two were included for meta-analysis. Pooled estimates showed decreased SBP (pooled mean difference (MD), -5.10; 95% confidence interval (CI), -11.34, 1.14; p > 0.05, p = 0.11), increased DBP (pooled MD, 0.45; 95% CI, -4.24, 5.13; p > 0.05, p = 0.85), decreased serum creatinine (pooled MD, -0.38; 95% CI, -0.83, 0.07; p > 0.05, p = 0.10) and maintained eGFR (pooled MD, 4.72; 95% CI, -1.85, 11.29; p > 0.05, p = 0.16) in the telehealth group. There was no significant difference from the control group. MAP (MD, 0.6; 95% CI, -6.61, 7.81; p > 0.05, p = 0.87) and BP control rate ( p > 0.05, p = 0.8), respectively, shown in two studies also demonstrated no statistical significance in the telehealth group.Conclusions: There was no statistically significant evidence to support the superiority of telehealth for BP management in CKD patients. This suggests further studies with improved study design and optimised intervention are needed in the future. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

11. Ginkgo biloba Extract for Patients with Early Diabetic Nephropathy: A Systematic Review

Author

Zhang, Lei, Mao, Wei, Guo, Xinfeng, Wu, Yifan, Li, Chuang, Lu, Zhaoyu, Su, Guobin, Li, Xiaoyan, Liu, Zhuangzhu, Guo, Rong, Jie, Xina, Wen, Zehuai, and Liu, Xusheng

Subjects
Article Subject
Abstract

Objectives. To evaluate the effectiveness and safety of a Ginkgo biloba extract for patients with early diabetic nephropathy. Methods. Randomised controlled trials (RCTs) conducted on adults with early diabetic nephropathy which used Gingko biloba extract were included. The major databases were searched, and manufacturers of Gingko biloba products were contacted for information on any published or unpublished studies. Two authors independently extracted the data from the included studies. Data analysis was conducted using Review Manager 5.0 software. Results. Sixteen RCTs were included. Ginkgo biloba extract decreased the urinary albumin excretion rate (UAER), fasting blood glucose (FBG), serum creatinine (SCR), and blood urea nitrogen (BUN). The extract also improved hemorheology. The methodological quality in the included studies was low. The explicit generation of the allocation sequence was described in only 6 trials. None of the included trials were confirmed to use blinding. Three studies had observed adverse events. One study using angiotensin-converting enzyme inhibitor (ACEi) reported mild cough in both groups. No serious adverse effects were reported. Conclusions. Gingko biloba extract is a valuable drug which has prospect in treating early diabetic nephropathy, especially with high UAER baseline level. The safety for early diabetic nephropathy is uncertain. Long-term, double-blinded RCTs with large sample sizes are still needed to provide stronger evidence.

Published
2013
Full Text
View/download PDF

12. Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease

Author

Mao, Wei, primary, Zhang, Lei, additional, Zou, Chuan, additional, Li, Chuang, additional, Wu, Yifan, additional, Su, Guobin, additional, Guo, Xinfeng, additional, Wu, Yuchi, additional, Lu, Fuhua, additional, Lin, Qizhan, additional, Wang, Lixin, additional, Bao, Kun, additional, Xu, Peng, additional, Zhao, Daixin, additional, Peng, Yu, additional, Liang, Hui, additional, Lu, Zhaoyu, additional, Gao, Yanxiang, additional, Jie, Xina, additional, Zhang, La, additional, Wen, Zehuai, additional, and Liu, Xusheng, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results